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ABSTRACT
Cancer is a group of diseases that affects 1.6 million and kills nearly 600,000 Americans
each year. The National Cancer Institute defines it as “diseases in which abnormal cells divide
without control and can invade nearby tissues” and it is often treated with one or more of the
following: chemotherapy, radiation, surgery. The expense for these treatments is expected to rise
to $156 billion by 2020. Localized delivery can improve effectiveness and cancer survival rates,
decrease the cost of treatment, and decrease the side effects of chemotherapy. This paper addresses
models for this localized delivery through nanoemulsions. Nanoemulsions are a spherical layer of
a hydrophobic substance holding and surrounded by hydrophilic substances or a spherical layer of
a hydrophilic substance surrounded by and holding hydrophobic substances with a diameter less
than one micrometer. Nanoemulsions are in development for cancer treatment due to their
thermodynamic stability, which improves shelf-life.
While nanoemulsions on their own do not provide specific targeting, two potential options
for targeted and local delivery are addressed here. This paper explores the effect of AS1411, an
aptamer which can target some cancer cells, on nanoemulsions for chemotherapy delivery.
AS1411 binds to nucleolin, which is overexpressed in many cancer cells and appears on their
surface, allowing AS1411 to target them. AS1411 also has the ability to inhibit cancer cell
functions and kill cancer cells selectively. When taken into healthy cells, AS1411 is removed
through exocytosis or efflux instead of damaging them. Using AS1411 on nanoemulsions should
cause the cancerous cells to actively absorb the nanodroplets while limiting uptake by healthy
cells.
Ultrasound-induced vaporization is also explored as a way to cause nanoemulsions to
release their payload into cancer cells. Vaporization of the nanoemulsion droplets weakens
surrounding membranes and forces drugs out of nanoemulsions as microjets. This method can be
used on many cancers, especially those near to the skin as there is less interference. One caveat is
that ultrasound may not be safe for lung cancer treatments, as ultrasound cannot penetrate air in
the lungs and the reflected waves may damage healthy lung tissue. These additions to systemic
nanoemulsion treatment, both combined and separate, are tested on both traditional single-layer
iv

MDA-MB-231 breast cancer cells and on artificially grown tumors, called spheroids. This
spheroid testing allows for a look into how these treatments may be affected by avascular tumors,
which are more drug resistant than normal cancer.
To test the effects of these treatment options, FITC-labeled or doxorubicin-loaded
nanoemulsions were produced and applied on top of the cancerous cells. Doxorubicin was used
due to its chemotherapeutic properties and its lack of interference with MTT assay readings. Some
samples were created with AS1411 covalently bound to the outside while others were created with
no payload or targeting to act as a control. After a period of incubation the nanoemulsions in some
samples are ultrasonicated while others remain untouched as control. Following further incubation,
the cells were harvested and assayed for analysis, using flow cytometry for FITC detection and an
MTT assay for doxorubicin-induced cytotoxicity detection.
The results of these tests showed that ultrasound improved cytotoxicity in doxorubicintreated spheroids but worsened FITC uptake. This reduced FITC uptake may be caused by holes
in the cell membrane induced by ultrasound, allowing FITC to leak back out of the cells. AS1411,
both with and without ultrasound, had an insignificant effect on cytotoxicity in this study. The lack
of consistent improvement by AS1411 may be due to the use of cancerous cells exclusively in our
spheroids, which result in all of the nanoemulsions releasing their payloads onto the cancer
regardless of whether or not they bind to their nucleolin. Another theory is that the incubation
times were too long, so the passive uptake of the nanoemulsions was able to overshadow to the
active uptake stimulated by AS1411. The results of this research encourage further study into the
potential efficacy of these treatment options.
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NOMENCLATURE
Spheroid = An artificially grown tumor in a nearly spherical shape.
Nanoemulsion = A drop of oil in water or a drop of water in oil ranging between 20 and 200 nm.
AS1411 = A chain of DNA that reads 5’-GGTGGTGGTGGTTGTGGTGGTGGTGG-3’. It has
been shown to have both anti-cancer and cancer targeting properties.
Doxorubicin =A common chemotherapeutic drug used in patients and in research.
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INTRODUCTION
Cancer is a group of diseases in which body cells grow abnormally and damage other cells.
It is a growing global concern and is now responsible for one in every six deaths, making it the
second leading cause of death worldwide (WHO). The market for cancer treatment in the United
States is growing (NCI) and new treatments are constantly in development. Traditional
chemotherapy kills rapidly multiplying cells, which also results in damage to normal tissues, such
as bone marrow, hair, and digestive tract tissues (ACS). To enhance the effectiveness of
chemotherapy on cancerous cells and limit these side effects, targeted delivery is being researched.
This paper addresses adaptations to nanoemulsion delivery to become a targeted therapy.
Nanoemulsions are a type of nanoparticle where a layer of hydrophobic material surrounds
a hydrophilic core or a hydrophilic material surrounds a hydrophobic core. These particles can be
used as drug vehicles to protect and carry chemotherapies throughout a body. Nanoemulsions are
also small enough (50-200 nm) to pass through leaky vasculature and accumulate in tumors,
resulting in higher delivery to cancer cells (Zhou). Ultrasound can be applied to perfluorocarbonbased nanoemulsions and can cause them to vaporize due to the low boiling point of the
perfluorocarbon. This process can induce cavitation of the vaporized droplets, which can result in
microstreaming and enhance drug delivery to nearby cells whose membranes were permeabilized
by the ultrasound (Zhou). While vaporization and cavitation cannot target individual cell types,
ultrasound can be focused to an area to specifically vaporize nanoemulsions there, resulting in
localized delivery.
AS1411 is an aptamer discovered by Bates et al. which binds to nucleolin. It is 26
nucleotides long and reads 5’-GGTGGTGGTGGTTGTGGTGGTGGTGG. AS1411 is removed
via efflux in normal cells, but in cancer cells is absorbed by micropinocytosis and increases in
concentration (Bates). AS1411 also binds to nucleolin that appears on the membranes of cancer
cells, allowing it to function as a targeting molecule (Luo et al.).
Spheroids are artificially grown tumors. The use of spheroids in these experiments should
allow for greater understanding of how these treatments will function in a 3D environment before
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performing in vivo experimentation (Ivascu). Ultrasound cavitation, due to the creation of
microjets, should be able to deliver drugs further into spheroids compared to spheroids not treated
with ultrasound. Concerns have been raised that this cavitation could break cells off the tumor and
induce metastasis, but no tests have been performed yet to verify this concern. If this is also true
in vivo, ultrasound should improve the speed at which drugs kill cancer cells and give the cancers
less time to metastasize. While AS1411 is not anticipated to have an additional effect on spheroids
compared to flat tissue, spheroids should provide a more accurate model of drug delivery for in
vivo comparisons. A photo of one spheroid from this lab is presented below as Figure 1.

Figure 1: A photo of an MDA-MB-231 spheroid grown in this lab

This project explores how AS1411 and ultrasonication each affect the uptake of
chemotherapeutic nanoemulsions into cancer cells in spheroid formations. The uptake of AS1411
into tumors has been tested before using fluorescent compounds, PGG-PTX, which is a
nanoparticle-forming chemotherapy drug, and spheroids (Luo, et al.). The use of nanoemulsions
to improve drug delivery to spheroids has also been tested, such as in the treatment of human
mammary cancer cells with photodynamic therapy (Muehlmann, et al.). This project offers greater
insight into how to improve cancer therapies by combining these augmentations to traditional
2

therapy and testing the combined treatment against both controls and the two augmentations alone.
This is improved by the use of spheroids to simulate the three-dimensional tissue growth of tumors
in vivo.
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INSTRUMENTATION AND EQUIPMENT
Spheroid Production:
Spheroids were produced using MDA-MB-231 human breast carcinoma cells. Additional
materials used were Trypsin-EDTA 0.05% (1 mL Trypsin-EDTA 0.25%: 4 mL PBS), sterile PBS,
deionized (DI) water, Dulbecco’s Modified Eagle Medium (DMEM) cell culture media, dry agar
powder, autoclave-safe 250 mL flasks, an autoclave, a microwave, a sterile hood, 24-well and 96well plates, 96-well Corning ultra-low attachment spheroid plates, a hemocytometer, a shaker with
speed of at least 120 rpm, a centrifuge with speed of at least 1500 rpm, pipettes, and pipette tips.
MTT Assay Protocol:
To perform the MTT assay, the following materials were used: MTT solution, lysis buffer,
Trypsin-EDTA 0.25%, a plate reader, pipettes, and pipette tips.
Cell Splitting/Harvesting
To split and harvest cells the following materials were used: 10/25 mL cell flasks, MDA-MB-231
Cells, Trypsin-EDTA 0.25%, Sterile PBS, deionized (DI) Water, Dulbecco’s Modified Eagle
Medium (DMEM) media, a sterile hood, formaldehyde, pipettes, and pipette tips.
Nanoemulsion Production
To produce nanoemulsions, the following materials were used: Cy5-AS1411 aptamer, AS1411thiol aptamer, Tris(2-carboxyethyl)phosphine (TCEP), sodium phosphate buffer, maleimide lipid,
an aspirator, doxorubicin hydrochloride, ice, a centrifuge, a sonicator, an extruder, and 200nm
membranes.
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PROCEDURE
Spheroid Production (Agar Method)
Prepare 1.25% Agar for coating non-tissue culture treated plates:
An autoclave safe 250 mL bottle was pre-warmed in a 40 oC water bath. 90mL of deionized H2O
(DI water) was heated in the 250 mL bottle to 80-90 oC using a hot plate. A cap was placed on the
flask at this point to prevent evaporation. 1.25 g of dry agar was added to the bottle and stirred
with a glass rod until the lumps disappeared. The total volume of the bottle was raised to 100mL
by adding DI water while the solution was being heated. The final solution was stirred with a
magnetic stir bar until thoroughly mixed. The agar solution, still loosely capped, was autoclaved
for 15 minutes at 121 oC using slow exhaust. The bottle was removed from the autoclave and
allowed to cool prior to the cap being tightened. The solution was stored at room temperature.

Agar coating of non-tissue culture treated plates (sterile conditions):
The agar was warmed to its melting point (approximately 70 oC) by microwaving it at 30 power
for 3 minutes followed by 100% power for 30 seconds. 200 µL (for a 24-well plate) or 100 µL (for
a 96-well plate) of the agarose was pipetted into each well of a plate. The agar was pipetted up and
down a few times in the hot agar to avoid dripping. The pipetting was done with smooth movement
around the well. The tip of the pipet was changed every 12 samples to avoid agar building up and
blocking it. The plate was stored at room temperature under sterile condition. After a few hours,
the plate was checked to see if the agar had fully solidified, so cells could be plated.

Create spheroids (sterile conditions):
Human cancer (MDA-MB-231) cells were detached from 80% confluency using 0.05% trypsin.
The cells were counted and centrifuged at 1500 rpm for 5 minutes in 4 oC. The amount of DMEM
required for a final cell concentration of 100,000 cells/mL (24-well plate) or 60,000 cells/100 µL
(96-well plate) was calculated using the cell count. The trypsin was aspirated and the cells were
suspended in the amount of DMEM calculated. In the event that far more DMEM was required to
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dilute the cell count than was needed to grow spheroids, some of the cells would be discarded. 1
mL (24-well plate) or 100 µL (96-well plate) of cells and media were pipetted into each well of a
round bottom ultra-low attachment plate (Corning Inc., Corning, NY, USA) or an agar treated flat
bottom plate created in a previous step. The lid was placed on each plate and the plate was shaken
at 120 rpm for 15 minutes to allow for aggregation. The cells were incubated for 37 oC for 3 to 7
days.

Spheroid treatment and disaggregation:
After the spheroids were formed, various concentrations of treatments were applied to each well
after being diluted to 1 mL per well (24-well plate) or 100 µL per well (96-well plate). A negative
control (no treatment) and a positive control (all cells are killed) are applied to some wells for
comparison. The spheroids are incubated for a set period of time. For 24-well plates, 1600 µL of
media was removed from each well using a 200 µL pipet eight times and 600 µL of fresh trypsin
was added to disaggregate the spheroids. For 96-well plates, 150 µL was removed from each well
using a 200 µL pipet and 150 µL of fresh trypsin was added. The plates were then incubated for at
least one more hour before being pipetted 3-5 times to disaggregate the spheroids. Cell viability
was measured via MTT Assay.

MTT Assay Protocol:
0.1 mL (24-well plate) or 10 µL (96-well plate) of 5 mg/mL stock MTT solution was added to
each well. Each well was incubated for 4 hours at 37 oC before 1 mL (24-well plate) or 100 µL
(96-well plate) of lysis buffer was added to each well. The final solution was incubated overnight
at 37 oC and read on a plate reader.

Cell Splitting
The source flask was examined under a microscope and the confluency of the cells was estimated.
Cells were harvested when between 80%-90% confluency. 0.25% Trypsin and DMEM media were
warmed to room temperature in a water bath. The source flask was held upside down and tiled so
that the cap faced upwards. The cap was unscrewed and the media was aspirated from the corner
it was in (not a corner cells had grown on). Touching the sides of the flask the cells grew on was
6

avoided. The flask was washed with 3 mL PBS (10 mL flask) or 10 mL PBS (25 mL flask) before
the PBS was aspirated using the stated technique. 3 mL (10mL flask) or 10 mL (25 mL flask) of
0.25% Trypsin-EDTA was added to the flask. If the cells were to be used in spheroid production
immediately, 0.05% Trypsin-EDTA was used instead, as per the spheroid protocols our lab uses.
The cells were incubated at 37 oC for 1 minutes (0.25% trypsin) or 3 minutes (0.05% trypsin). The
side of the flask was tapped vigorously to shake the cells loose and the flask was placed under a
microscope. If some of the cells were not moving, the flask was tapped more. If, after two rounds
of tapping, some cells still remained immobile, the flask was incubated for an additional minute
before being tapped again. The trypsin was neutralized with 3 mL of DMEM for 10 mL flasks (the
25 mL flasks did not require neutralization before transfer). A cell count was performed if required.
X mL of cells were moved to the new flask and 10-X mL media was added to the new flask where
X is 8/2(number of days until next splitting). The new flask was incubated at 37 oC, the remaining cells were
aspirated and the old flask was disposed of in the biological materials waste bin.

Cell Harvest Protocol
This was performed at a set time following treatment. The media from the cell flask was aspirated
and replaced with 500 µL of PBS. This PBS was then aspirated and replaced with 300 µL of
trypsin. The flask was placed in an incubator for 1-2 minutes until the cells detached. The
cell/trypsin mixture was pipetted into a 1.5 mL microcentrifuge tube with 300 µL media. The tube
was centrifuged at 1500g for 5 minutes. A pipette was used to remove 400 µL of the supernatant,
which was replaced with 200 µL of 4% formaldehyde. The sample was stored at 4oC until needed.

Cell Fixing Protocol
This was performed at a set time following treatment. The media was aspirated and 100 µL of PBS
was added to each well of the 96-well plate. 200 µL of 4% formaldehyde was added to each
sample before they were stored at 4 oC.
Nanoemulsion Production
Thiol-Maleimide conjugation protocol
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A vacuum was applied to the maleimide lipid solution for 5 minutes. 200 µL deprotected AS1411
was added to 800 µL maleimide lipid before the solution was stored at 4 oC overnight.

For Fluorescent Aptamer Deprotection:
132 µL of 100 mM sodium phosphate buffer, 15 µL 0.05 mM fluorescent aptamer (Cy5-AS1411)
and 3 µL of 500 mM TCEP were added to a 1.5 mL centrifuge tube. 132 µL of 100 mM sodium
phosphate buffer to a 1.5 mL centrifuge tube. The tube was gently mixed and incubated at room
temperature for at least 1 hour. Exposing the fluorescent solutions to light was avoided.

For Non-fluorescent Aptamer Deprotection:
172 µL of 100 mM sodium phosphate buffer, 20 µL of 2 mM AS1411-thiol aptamer, and 8 µL of
500 mM TCEP were added to a1.5 mL centrifuge tube. The tube was gently mixed and incubated
at room temperature for at least 1 hour.

Doxorubicin Nanoemulsion Production
80 µL PFC and 5.8 µL of 17.24 mM doxorubicin hydrochloride solution was added to 200 µL of
lipid solution (final concentration of doxorubicin was 500 µM in lipid) in a 15 mL tube. The tube
was sonicated on ice at standard settings (60% amplitude, 5 cycles of 20 seconds on and 40 seconds
off). The droplets were washed with centrifugation (2000g for 3 minutes at room temperature).
The supernatant was removed and the pellet was re-suspended in 1 mL of PBS. The nanoemulsions
were extruded through 200 nm membranes seven time and the final solution was stored in a 1.5
mL centrifuge tube.

Empty Nanoemulsion Production
80 µL PFC and 5.8 µL PBS were added to 200 µL of lipid solution in a 15 mL centrifuge tube.
The tube was sonicated on ice at standard settings (60% amplitude for 5 cycles of 20 seconds on,
40 seconds off). The droplet emulsion was washed via centrifugation at 200g for 3 minutes in room
temperature. The supernatant was removed and the pellet was resuspended in 1 mL PBS. The
solution was extruded through 200 nm membranes 7 times. The final solution was stored in a 1.5
mL centrifuge tube.
8

Ultrasound Testing
Fluorescent nanoemulsions were produced and applied to both single-layer and spheroid
cancer cells. After 1 hour, half of the nanoemulsions were placed under ultrasound treatment for a
fixed period of time. A one hour waiting period was chosen to allow for the nanoemulsions to
potentially bind to receptors on the spheroid without too much passive uptake into the cells. Both
ultrasound-treated and non-ultrasound treated emulsions were then be placed in incubation for an
additional 2 days before results were obtained. Some samples were examined via flow cytometry.
Other samples were sent through a plate reader for fluorescent reading.

RESULTS AND DISCUSSION OF RESULTS
1. Spheroid Production:
Spheroids were produced with two methods to determine which was more consistent. The first
method involved treating a normal 96-well plate with agar before attempting to grow cells. The
second method was to use specially made spheroid plates with round, treated bottoms to prevent
cell attachment. Spheroid size and shape were visually examined and photos were taken of both
results. The method that produced uniformly sized spheroids with low aspect ratios was used in
additional experiments. It was found that the spheroid plates performed better, as their round
bottoms and surface treatments encouraged more consistent aggregation. As evidenced by Figure
2 below, there is not a statistical difference between using 10k of cells and 15k of cells.
Additionally, there is no statistical difference between using 5 and 50 µM of doxorubicin, though
there is a difference between Control and every other concentration and 0.5 µM and every other
concentration when testing the various sized spheroids.
Figures 3 and 4 show the shape of spheroids and how high concentrations of doxorubicin
disaggregate them. Figure 5 shows why other experiments were performed after 28 hours of
treatment, as the standard deviation for MTT absorbance was consistently smaller with less time.
The nanoemulsion data was not normal, so ANOVA could not be performed, but they do show
that for liquid doxorubicin the control group and 5 µM liquid doxotubicin group there is no
statistical difference in absorbance, but there is a difference between each of 50 µM and 25 µM
and the others.
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Average Absorbance vs. Doxorubicin
Concentration and Seeding Cell Density

Absorbance at 570nm

0.3
0.25
0.2
0.15
0.1
0.05
0
Control

0.5µM Dox

5µM Dox

50µM Dox

Liquid Doxorubicin Concentration
5k cells

10k cells

15k cells

Figure 1: MTT absorbance vs. doxorubicin concentration and seeding cell density

Figure 2: 15k seeded spheroid after 5 days of growth and 50µM doxorubicin (left) and a 15k seeded spheroid after 5 days of
growth and no doxorubicin treatment (right) (spheroid plate, cropped)
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Normalized Absorbance at 570nm

Average Absorbance of Doxorubicin Treated
Spheroids After 2 or 4 Days of Treatment.
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
PBS

5µM Free
Dox

25µM Free
Dox

50µM Free
Dox

Blank
Emulsions

0.73µM Dox 3.65µM Dox 7.3µM Dox
Emulsions
Emulsions
Emulsions

Doxorubicin Concentration
2 Days

4 Days

Figure 3: Absorbance of MTT treated spheroids following doxorubicin treatments at different times

2. Nanoemulsion Testing
Doxorubicin nanoemulsions were produced and placed into 5 wells of a clean 96 well plate,
with 100 µL per well. Three wells were also filled with each of the following: 0.58%
doxorubicin (the total concentration of doxorubicin in the nanoemulsion if all the
doxorubicin used entered the nanoemulsions, or the theoretical loading) 0.058%
doxorubicin, 5.8x10-3% doxorubicin, 5.8x10-4% doxorubicin, and 5.8x10-5% doxorubicin.
100 µL was used here as well. Then each well received 100 µL of 4% methanol, which
ruptured the nanoemulsions and allowed the doxorubicin to be released into solution. Since
each sample had the same amount of methanol, a methanol background test was not
necessary as any background reading would be the same for each sample. The fluorescence
of the doxorubicin was read via a plate reader, and the concentration of doxorubicin in the
nanoemulsions was estimated to be 14.6% of the maximum value, calculated from a
polynomial curve that fits the data down to 5.8x10-5% doxorubicin within the linear range
of the polynomial curve, which results in a value of 0.08468% or 14.60 µM. This loading
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efficiency was used in interpreting all nanoemulsion data in this paper as they were
produced under the same conditions as all of the batches. .
The size of the nanoemulsions was determined by diluting 12-day-old doxorubicin
nanoemulsions in water and placing the solution in a NanoBrook ZetaPALS potential
analyzer. The sample was scanned with a 658nm laser and the scattering within indicated
the range of sizes for the nanoemulsions. The effective diameter was measured to be 703
nm, which may have weakened penetration and thus effecasy but smaller nanoemulsions
could be created using smaller filters.
Additionally, the integrity lifespan of the nanoemulsions was tested by measuring the
fluorescence of flat cells treated with FITC and AS1411/Cy5 FITC nanoemulsions which
had been stored for up to 2 weeks after production. The FITC nanoemulsions contained
FITC liquid while the AS1411/Cy5 FITC nanoemulsions contained FITC liquid and had
AS1411/Cy5 bound to the membrane. The effectiveness of these nanoemulsions was
determined by counting the cells that contained FITC or Cy5 after treatment and fixing to
show how many cells would receive treatment with chemotherapeutic nanoemulsions. The
results of this study are seen in Figure 6, with the controls being no treatment. The results
show no difference between one day and one week as each is within one standard deviation
of the other. After two weeks, significant leaking of the FITC was seen and fewer cells
were marked when total cell association was tested after washing.
Doxorubicin was used for the drug tests due to its chemotherapeutic properties.
Doxorubicin has an IC50 Z-Score of 1.16291 on MDA-MB-231. A Z-Score of 2 or above
indicates the cell line is resistant to the drug while a Z-Score of -2 or below indicates it is
sensitive to the drug (Cancer RxGenes). The effect of doxorubicin on these cells has also
been shown experimentally in our lab during a previous experiment. In Figure 6, the
percent viability of flat MDA-MB-231 cells can be seen decreasing as doxorubicin
concentration increases.

12

% Viability

Percent Viability of MDA-MB-231 Cells Following
Doxorubicin Treatment
150%
100%
50%
0%
0

2
5
10
25
Doxorubicin Concentration (µM)

50

Figure 6: Percent Viability of MDA-MB-231 Cells Following Doxorubicin Treatment

Normalized Fluorescence

Comparison of Fluorescence in Cells Treated with
Variably Aged Nanoemulsions
3.5
3
2.5
2
1.5
1
0.5
0
Day 1
Control

Day 8
Day 1
Day 8
Day 1
Control Untargeted Untargeted Targeted

Day 8
Targeted

Day 15
Targeted

Age and Type of Nanoemulsion Used
FITC

CY 5

Figure 6: Weekly fluorescence test to determine nanoemulsion lifespan through treatment of flat cells.

3. AS1411 Testing (Fluorescent)
AS1411 and non-AS1411 fluorescent nanoemulsions were produced and applied to both
single layer and spheroid cancer cells. The cells were then be returned to incubation for 2
days before being examined. Some samples were examined via flow cytometry. Other
samples were sent through a plate reader for fluorescent reading. It was expected that the
AS1411 nanoemulsions would result in more fluorescence within the cells as they bind to
nucleolin. However, since there only tumor cells were tested, the effect may not be
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noticeable, as AS1411 is used to cause the nanoemulsions to specifically target cancer
tissue instead of healthy tissue.
4. AS1411 Testing (Drug)
AS1411 and non-AS1411 modified doxorubicin-loaded nanoemulsions were produced and
applied to both single-layer cancer cells and spheroids. After two days of exposure in
incubation, results were obtained. To measure cell viability, some sets were tested with an
MTT assay after 2 days of growth. This two day waiting time was chosen based on the
results of an experiment seen in Figure 5, as two days resulted in less variance than four
days. It was expected that the AS1411 nanoemulsions would result in less cell viability,
but this may be less noticeable for the reasons mentioned above as no non-cancer controls
were used. As Figures 6 and 7 show below, there are inconsistent differences between the
AS1411-targeted and untargeted nanoemulsions, with large standard deviations within
some samples. An ANOVA for Figure 6 shows that both emulsion concentration and
doxorubicin presence have statistically significant effects on the absorbance, but AS1411
does not. AS1411 combined with emulsion concentration is shown to be statistically
significant, but the results are clearly influenced by what are likely outliers, as the presence
of AS1411 is shown to worsen the effect of some nanoemulsion concentrations. An
ANOVA of Figure 7 could not be performed due to low R-Squared value (50.39%) found
through Minitab. The background reading from blank nanoemulsions were not subtracted
from the values as the presence of nanoemulsions weakened absorbance as seen between
the No Emulsion and Drugless groups.
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% Viability as Determined via
Absorbance at 570nm

% Viability of Spheriods Measured via
Absorbance Following Ultrasonicated
Nanoemulsion Treatment
150.00%
100.00%
50.00%
0.00%

Doxorubicin Nanoemulsion Concentration
No AS1411

AS1411

Figure 7: Percent Viability determined via plate reading for MTT treated (2 hour incubation) spheroids treated with doxorubicin
nanoemulsions and ultrasound.

Normalized Absorbance at 570nm

Average Absorbance of Non-Ultrasonicated
Nanoemulsions
2
1.5
1
0.5
0

Doxorubicin Nanoemulsion Concentration
No AS1411

AS1411

Figure 8: Average plate reading for MTT treated (2 hour incubation) spheroids treated with un-sonicated doxorubicin
nanoemulsions.
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Normalized Absorbance of Spheroids
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Control Drugless 0.0146
µM

0.073
µM

0.146
µM

0.365 0.73 µM 1.095 1.46 µM
µM
µM

Doxorubicin Concentration from Nanoemulsions
No US, No AS1411

US, No AS1411

No US, with AS1411

US, with AS1411

Figure10: The combined data from Figure 8 and 9. The normalized values of the absorbance from spheroids

1. Ultrasound Testing (Fluorescent)
It was expected that the ultrasound-treated spheroids would have absorbed more of the
fluorescent material, resulting in a higher flow cytometry reading as the fluorescent
molecules were delivered into the cell, and a lower pate reading as less MTT was converted
due to greater cytotoxicity.
2. Ultrasound Testing (Drug)
Doxorubicin-loaded nanoemulsions were produced and applied to both single-layer and
spheroid cancer cells. After 1 hour, half of the nanoemulsions were placed under ultrasound
for a fixed period of time. Both ultrasound-treated and non-ultrasound treated emulsions
were then placed in incubation for an additional 2 days before results were obtained. To
measure cell viability an MTT assay was applied to some sets, the results of which are seen
in Figure 8. Here, both nanoemulsions and liquid doxorubicin were tested with and without
ultrasound. ANOVA could not be performed due to a low r-squared value of 38.82%. It
was expected that the ultrasound-treated spheroids would be less viable compared to
untreated spheroids. The liquid doxorubicin ANOVA for Figure 9 showed that the
doxorubicin concentration had some effect on absorbance, but ultrasound did not, which
was expected without nanoemulsions. Figures 9 and 10 confirms this by comparing
treatments of liquid doxorubicin with and without ultrasound, although the data was too
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far from a normal distribution to perform an ANOVA. Figure 10 shows an unexpected
increase in absorbance as doxorubicin concentration increases, but this may be due to
doxorubicin being a similar color to the product of MTT assays, resulting in false positives.
Since the goal of this experiment was to determine the effects of ultrasound and the samples
are compared against those treated with the same amount of doxorubicin, this does not
change the conclusion.

Normalized Absorbance at 570nm

Average Absorbance of Spheroids Treated With
Doxorubicin Liquid or Nanoemulsions With and
Without Ultrasonication
1.2
1
0.8
0.6
0.4
0.2
0
PBS

0.5µM
Dox

2.5µM
Dox

5.0µM
Blank 0.146 µM 0.73 µM 1.46 µM
Dox Emulsions Emulsion Emulsion Emulsion

Doxorubicin Concentration
No Ultrasound Treatment Average

Ultrasound Treated Average

Figure 9: Absorbance of MTT treated spheroids following doxorubicin treatment. Each emulsion sample contained 10µL of
nanoemulsions, with the percentage indicating the amount that contained doxorubicin. Ultrasound occurred 30 minutes
following nanoemulsion place
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Normalized Absorbance at 570nm

Average Absorbance of Doxorubicin Treated
Spheroids With and Without Ultrasound
2.5
2
1.5
1
0.5
0
PBS

1µM

2µM

2.5µM

3µM

4µM

5µM

Doxorubicin Volume
No Ultra Sound

Ultra Sound

Figure 10: Absorbance of MTT treated spheroids following liquid doxorubicin treatment

3. Combined Testing (Fluorescent)
AS1411 and non-AS1411 conjugated fluorescent nanoemulsions were produced and
applied to both single-layer cancer cells and spheroids. After 1 hour, half of each type was
placed under ultrasound for a fixed period of time. Then, all samples were returned to
incubation for 2 days. For each sample type half of the wells were examined via flow
cytometry while the other half were examined in a plate reader. It was expected that the
AS1411/ultrasound cells would have the most fluorescence. The next most fluorescent
would be ultrasound, followed by AS1411, as AS1411 is expected to less of a noticeable
effect without noncancer cells to differentiate cancer from. Finally, the control is expected
to have the least fluorescence. We can see in Figure 11 below that the ultrasound-treated
cells had consistently lower fluorescence intensity than the non-ultrasound treated cells and
that AS1411 improved the cell counts. Figure 11 was normalized to the untargeted, nonultrasonicated samples as untreated samples were not used in this experiment. A similar
experiment that shows how these treatments compare to a control can be seen in Figure 7.
This can be explained as the ultrasonication creating holes in the cells allowing for the
FITC to escape. Testing this on spheroids, as seen in Figure 12, shows less effect. The
FITC intensity could not be tested in ANOVA due to a low R-squared value, while the Cy5
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intensity showed only the presence of Cy5/AS1411 and the combination of that presence
with ultrasound to be significant. Specifically, the presence of Cy5/AS1411 increased the
intensity while adding ultrasound to Cy5/AS1411 treated cells lowered it. The severe
differences between Figures 11 and 12 are likely due to the use of flat cells in Figure 11
and spheroids in Figure 12 or the immediate fixing of the cells in Figure 12’s experiments.

FITC intensity in non-spheroid cancer cells
1.4

Normalized FITC Intensity

1.2
1
0.8
0.6
0.4
0.2
0
NoUS Untargeted

US Untargeted

NoUS AS1411

US AS1411

Cell Treatments
Figure 11: Normalized values from Total Cell Association Flow Cytometry MACS Quantity Analyzer reading of FITC in flat cells
after various treatments for 1 hour. (1=3341.7 cells)

Normalized Fluorescence Intensity

FITC intensity following treatments of spheroids
1.4
1.2
1
0.8
0.6
0.4
0.2
0
No US
Control

No US
Untargeted

No US
AS1411

US Control

US
Untargeted

USAS1411

Treatments on Spheroids
FITC

Figure 12: A normalized graph showing the cells counted via Total Cell Association Flow Cytometry MACS Quantity Analyzer
containing FITC or Cy5 immediately following ultrasound treatment of spheroids (1=158.5 cells)
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4. Combined Testing (Drug)
AS1411 and non-AS1411 conjugated doxorubicin nanoemulsions were produced and
applied to both single-layer cells and spheroids. After 1 hour, half of each type were placed
under ultrasound before each sample was returned to incubate for 2 days. Samples were
treated under an MTT assay to measure viability. It was expected that the
AS1411/ultrasound cells would have the most fluorescence. The next most fluorescent
would be ultrasound, followed by AS1411. Finally, the control is expected to have the least
fluorescence.
Figure 13 shows the average absorbance from MTT assays of spheroids after nanoemulsion
treatments. Some values have large standard deviations or are simply abnormally large.
Unfortunately, no cause for these abnormalities have been found. Additional testing may
find these to be outliers. Additionally, ANOVA could not be performed, as the residual
tests were failed as seen in Figure 14. Specifically, the normal probability plot deviated
from the center line drastically and the versus fit is drastically large on the right side.

Normalized Absorbance at 570nm

Average Absorbance of MTT Treated Spheroids
vs. Nanoemulsion Treatments
6
4
2
0
Control

0.146µM

-2

0.365µM

0.73µM

1.095µM

1.46µM

Nanoemulsion Concentration
Blank No US

Blank US

Dox No US

Dox US

AS1411 Dox No US

AS1411 Dox US

Figure 13: Absorbance of MTT in spheroids following nanoemulsion treatments. The number of blank nanoemulsions in each
group is equal to the amount of nanoemulsions at that concentration of doxorubicin for drug emulsions.
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Figure 14: Residual Plots for the combined tests

CONCLUSIONS
Cancer continues to be a major source of mortality worldwide. This paper has presented a
plan to test two methods of localizing drug delivery in nanoemulsions. Combined, these methods
may result in fewer side effects for current and future cancer patients. AS1411 surface modification
has the potential to result in greater uptake into cancer cells specifically and greater accumulation
around the tumor. Ultrasound-induced vaporization of nanoemulsions has the potential to increase
penetration into the spheroid and increase drug uptake. Neither of these methods should affect
healthy tissue, although the ultrasound is area specific and could injure healthy tissue adjacent to
the tumor. The use of spheroids should result in more accurate comparisons to in vivo conditions.
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RECOMMENDATIONS
The results of this study leave many areas for future research. While the combined effects
of AS1411 and ultrasonication showed little increase compared to ultrasonication alone, this study
was limited by the use of only cancerous cells. Future studies can experiment using cancerous
spheroids and healthy tissue to see if AS1411 will encourage drug delivery to cancerous cells over
healthy cells. Similarly, this experiment could be performed with an artificial circulatory system
to see if the AS1411 will hold the nanoemulsions to the spheroids long enough for a high
concentration to build up there so that only a short period of ultrasonication is necessary for
treatment. If AS1411 is shown to contribute to the selectivity of the drug’s effects, in vivo testing
in animals may be warranted. This study has yielded initial results on ultrasound’s ability to
improve drug delivery in tumors in vivo and has revealed potential complications to avoid when
testing the effects of AS1411 on nanoemulsions. Additional studies may include testing other
chemicals to target cancer besides AS1411 and see how they influence uptake with ultrasound.
There is some concern that the physical structures of spheroids prevent MTT from reaching
cells in the center, skewing cell viability results. This was not anticipated in this paper and was not
accounted for, which may have resulted in the effects of the drugs being stronger than recorded
here. Future tests should involve a step disaggregating the spheroid without harming the cells prior
to MTT application. Other studies have used the CellTiter-Glo Luminescent Assay to disaggregate
the spheroids through lysis and determine the relative number of viable cells prior to lysing using
the ATP that was in the cells. There was also concerns that doxorubicin could interfere with the
absorbance of the crystals from the MTT assay. An absorbance test was performed, and while
doxorubicin does show some absorbance at 570nm, it is very minor, with its peak absorbance being
between 480 and 490 nm. Concerns were also raised that doxorubicin may be too easy of a drug
to enter cells, thus negating some of the effects of the drug delivery mechanisms. Due to these
concerns, it is suggested that future studies consider using other drugs to determine if these
concerns are valid.
Additional concerns are that the ultrasonication of nanoemulsions could induce metastasis
by breaking cells off the tumor and that the large nanoemulsions may impede uptake into
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spheroids. Future tests could verify the first concern by using MTT to test the viability of cells that
break off from the spheroid during ultrasound treatment. Further testing with smaller
nanoemulsions can test the effect of the second concern.
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